Strategies for Treating Myc-Positive DLBCL

For High-Definition, Click

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma, accounting for approximately one-third of lymphoma patients, according to Myron Czuczman, MD. Several prognostication strategies beyond the International Prognostic Index exist, including using fluorescence in situ hybridization (FISH) to test for Myc and/or BCL2 rearrangements. If a patient has both rearrangements, there is uncertainty about what treatments can be effective, which ultimately leads to a very poor prognosis.

There are a number of potential treatment options and data for Myc rearrangements, suggests Czuczman. This subtype of DLBCL can be treated with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) 14, R-CHOP, and ritxumiab, etoposide, prednisone, vincristine and doxorubicin hydrochloride (R-EPOCH).